8-K: Sangamo Therapeutics Files Chapter 11 Monthly Operating Reports

Sangamo Therapeutics, Inc. has filed its amended monthly operating reports for July and August 2026, and its monthly operating report for September 2026, detailing its financial activities during its Chapter 11 bankruptcy case.

Summary

• Sangamo Therapeutics, Inc. (the Company) filed its Chapter 11 voluntary petition for relief on June 23, 2026.
• The Company has submitted amended monthly operating reports (MORs) for July and August 2026, and its MOR for September 2026.
• These reports detail the Company's cash receipts, disbursements, asset and liability status, and income/loss for the respective periods.
• The Company's common stock was suspended from trading on Nasdaq on May 5, 2026, and delisted effective October 17, 2026, now trading on the OTC Expert Market.
• The MORs are unaudited and not prepared in accordance with U.S. GAAP, and should not be relied upon for investment decisions.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the ongoing Chapter 11 bankruptcy proceedings and the delisting of the company's common stock from Nasdaq.

Positives

• The Company continues to manage its operations and financial reporting during the Chapter 11 process.
• Significant asset sales in September 2026 generated substantial cash proceeds ($161 million).
• The Company repaid approximately $7.2 million of DIP obligations in September 2026.
• The Company's cash balance increased significantly by the end of September 2026, reaching $138.5 million.

Negatives

• The Company is in Chapter 11 bankruptcy proceedings.
• The Company's common stock has been delisted from Nasdaq and now trades on the OTC Expert Market, indicating severe financial distress.
• The MORs are not prepared under U.S. GAAP and are subject to future adjustments, limiting their reliability for investment analysis.
• The Company reported significant net losses in July and August 2026 (-$11.2 million and -$14.4 million respectively).
• The September MOR shows a substantial net profit of $143.8 million, primarily due to asset sales, but this is within the context of bankruptcy.

Risks

• The ongoing Chapter 11 bankruptcy case poses substantial risks to the Company's future operations and the recovery of creditor/shareholder value.
• Trading in the Company's common stock is highly speculative and carries substantial risks.
• The MORs are not prepared for investment decision-making and may not be complete or accurate from an investor's perspective.
• There is uncertainty surrounding the valuation and ownership of certain assets and liabilities.

Future Outlook

The filing primarily reports on past financial activities during the Chapter 11 proceedings and does not contain specific forward-looking statements or guidance regarding future business operations or financial performance beyond the reporting periods.

Management Comments

• The Company cautions investors and potential investors not to place undue reliance upon the information contained in the MORs, which were not prepared for the purpose of providing the basis for an investment decision.
• The MORs are limited in scope, cover a limited time period and have been prepared solely for the purpose of complying with the reporting requirements of the Bankruptcy Court.
• The MORs are not audited or reviewed by independent accountants, were not prepared in accordance with generally accepted accounting principles in the United States, are in a format prescribed by applicable bankruptcy laws or rules, and are subject to future adjustment and reconciliation.
• Trading in the Company's common stock during the pendency of the Chapter 11 Case is highly speculative and poses substantial risks.

Industry Context

StockSavvy.ai notes that the biotechnology sector is capital-intensive and subject to high failure rates. Companies undergoing Chapter 11 proceedings, especially after delisting from major exchanges, face immense challenges in restructuring, attracting new capital, and continuing operations. The significant asset sales reported in September suggest a strategic pivot or wind-down of certain operations.

Legal Proceedings

• Chapter 11 bankruptcy case filed in the United States Bankruptcy Court for the District of Delaware (Case No. 26-10989).

Stakeholder Impact

• Shareholders: Trading in common stock is highly speculative and poses substantial risks; recovery, if any, is uncertain.
• Creditors: The Chapter 11 process will determine the priority and extent of recovery for prepetition and postpetition creditors.
• Employees: The company has experienced a significant decrease in headcount, impacting current and former employees, particularly concerning equity-based compensation (RSUs) and retention programs.

Next Steps

• Continue to comply with monthly reporting requirements of the Bankruptcy Court.
• The Chapter 11 case is ongoing, with future steps dependent on the confirmation of a plan of reorganization.
• All remaining DIP Obligations were paid in full on October 5, 2026.

Key Dates

Recommendation

Given the company is in Chapter 11 bankruptcy and its stock has been delisted, a 'hold' recommendation reflects the extreme speculation and risk involved. While asset sales have improved liquidity, the ultimate outcome for equity holders remains highly uncertain and dependent on the successful confirmation and execution of a reorganization plan.

Keywords

Chapter 11, Bankruptcy, Monthly Operating Report, Asset Sale, DIP Financing, Delisting, Restructuring